Generic Invega Availability
See also: Generic Invega Sustenna
INVEGA (paliperidone - tablet, extended release;oral)
Manufacturer: JANSSEN PHARMS
Approval date: December 19, 2006
Strength(s): 3MG, 6MG [RLD], 9MG
Manufacturer: JANSSEN PHARMS
Approval date: August 26, 2008
Has a generic version of Invega been approved?
No. There is currently no therapeutically equivalent version of Invega available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invega. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Invega.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- July 31, 2012 - ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
- July 31, 2012 - TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
- January 31, 2013 - PEDIATRIC EXCLUSIVITY
- April 6, 2014 - NEW PATIENT POPULATION
- October 6, 2014 - PEDIATRIC EXCLUSIVITY
- Invega Consumer Information (Drugs.com)
- Invega extended-release tablets Consumer Information (Wolters Kluwer)
- Invega Consumer Information (Cerner Multum)
- Invega Advanced Consumer Information (Micromedex)
- Invega AHFS DI Monographs (ASHP)
- Paliperidone Consumer Information (Wolters Kluwer)
- Paliperidone extended-release tablets Consumer Information (Wolters Kluwer)
- Paliperidone Consumer Information (Cerner Multum)
- Paliperidone Advanced Consumer Information (Micromedex)
- Paliperidone Intramuscular Advanced Consumer Information (Micromedex)
- Paliperidone AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|